Luye Pharma Group Ltd (LUP) - Net Assets
Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has net assets worth €16.54 Billion EUR (≈ $19.34 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€32.03 Billion ≈ $37.45 Billion USD) and total liabilities (€15.49 Billion ≈ $18.11 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LUP financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €16.54 Billion |
| % of Total Assets | 51.64% |
| Annual Growth Rate | 11.57% |
| 5-Year Change | 94.51% |
| 10-Year Change | N/A |
| Growth Volatility | 10.97 |
Luye Pharma Group Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Luye Pharma Group Ltd's net assets have evolved over time, based on quarterly financial data. Also explore LUP total assets for the complete picture of this company's asset base.
Annual Net Assets for Luye Pharma Group Ltd (2016–2024)
The table below shows the annual net assets of Luye Pharma Group Ltd from 2016 to 2024. For live valuation and market cap data, see Luye Pharma Group Ltd (LUP) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €15.75 Billion ≈ $18.42 Billion |
+16.45% |
| 2023-12-31 | €13.53 Billion ≈ $15.82 Billion |
+22.52% |
| 2022-12-31 | €11.04 Billion ≈ $12.91 Billion |
+21.15% |
| 2021-12-31 | €9.11 Billion ≈ $10.66 Billion |
+12.53% |
| 2020-12-31 | €8.10 Billion ≈ $9.47 Billion |
-13.58% |
| 2019-12-31 | €9.37 Billion ≈ $10.96 Billion |
+18.12% |
| 2018-12-31 | €7.93 Billion ≈ $9.28 Billion |
+15.05% |
| 2017-12-31 | €6.90 Billion ≈ $8.06 Billion |
+5.09% |
| 2016-12-31 | €6.56 Billion ≈ $7.67 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Luye Pharma Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €14.15 Billion | 100.00% |
| Total Equity | €14.15 Billion | 100.00% |
Luye Pharma Group Ltd Competitors by Market Cap
The table below lists competitors of Luye Pharma Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Edadoc Technology Co. Ltd. A
SHE:301366
|
$1.18 Billion |
|
Yangtze Optical Electronic Co. Ltd. A
SHG:688143
|
$1.18 Billion |
|
DBV Technologies
NASDAQ:DBVT
|
$1.18 Billion |
|
KEDE Numerical Control Co Ltd
SHG:688305
|
$1.18 Billion |
|
Winall Hi tech Seed
SHE:300087
|
$1.18 Billion |
|
Ramsay Generale De Sante
PA:GDS
|
$1.18 Billion |
|
Ami Organics Limited
NSE:AMIORG
|
$1.18 Billion |
|
Medartis Holding AG
SW:MED
|
$1.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Luye Pharma Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,531,185,000 to 14,154,529,000, a change of 1,623,344,000 (13.0%).
- Net income of 471,886,000 contributed positively to equity growth.
- Other factors increased equity by 1,151,458,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €471.89 Million | +3.33% |
| Other Changes | €1.15 Billion | +8.13% |
| Total Change | €- | 12.95% |
Book Value vs Market Value Analysis
This analysis compares Luye Pharma Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.11 | €0.29 | x |
| 2018-12-31 | €2.38 | €0.29 | x |
| 2019-12-31 | €2.92 | €0.29 | x |
| 2020-12-31 | €2.52 | €0.29 | x |
| 2021-12-31 | €2.40 | €0.29 | x |
| 2022-12-31 | €2.96 | €0.29 | x |
| 2023-12-31 | €3.33 | €0.29 | x |
| 2024-12-31 | €3.76 | €0.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Luye Pharma Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.79%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 2.09x
- Recent ROE (3.33%) is below the historical average (9.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 13.87% | 30.56% | 0.32x | 1.43x | €248.68 Million |
| 2017 | 14.50% | 25.73% | 0.35x | 1.59x | €304.53 Million |
| 2018 | 16.69% | 25.19% | 0.29x | 2.25x | €522.53 Million |
| 2019 | 15.92% | 23.10% | 0.33x | 2.09x | €546.15 Million |
| 2020 | 8.95% | 12.76% | 0.27x | 2.61x | €-82.54 Million |
| 2021 | -1.58% | -2.58% | 0.23x | 2.66x | €-983.20 Million |
| 2022 | 5.94% | 10.11% | 0.25x | 2.38x | €-412.79 Million |
| 2023 | 4.25% | 8.67% | 0.24x | 2.03x | €-720.51 Million |
| 2024 | 3.33% | 7.79% | 0.20x | 2.09x | €-943.57 Million |
Industry Comparison
This section compares Luye Pharma Group Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $581,316,543
- Average return on equity (ROE) among peers: -36.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Luye Pharma Group Ltd (LUP) | €16.54 Billion | 13.87% | 0.94x | $1.18 Billion |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $4.11 Billion | 11.00% | 0.48x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $177.73 Million | 12.78% | 1.10x | $148.83 Million |
| Alkermes plc (8AK) | $1.46 Billion | 25.06% | 0.40x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $13.21 Million | -39.32% | 0.25x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $11.52 Million | -15.41% | 4.93x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $480.84K | -163.98% | 0.37x | $1.75 Million |
| Apontis Pharma AG (APPH) | $41.57 Million | 6.47% | 0.44x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more